Skip to main content
Premium Trial:

Request an Annual Quote

Abbott, Caprion Extend Cancer Antibody Partnership

NEW YORK (GenomeWeb News) — Abbott today said it has extended a research partnership with Caprion Proteomics to identify and use cancer antibody targets.
The agreement grants Abbott exclusive rights for up to two years to 10 lung cancer targets that Caprion found.
The new agreement extends an alliance the companies struck three years ago in which Abbott and Caprion used Caprion’s CellCarta proteomics platform to evaluate cell-surface drug targets by comparing plasma membrane proteins in normal tissues and cancer tissues.
Specific financial terms of the agreement were not released.
“From day one, the partnership with Caprion has resulted in a series of potential therapeutic antibody targets,” said Abbott divisional vice president Stephen Fesik said in a statement.
The new agreement will grant more time to wrap up pre-clinical evaluation of the 10 targets Abbott chose, Fesik added.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.